{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-089942","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.854186+00:00","generated_at":"2026-05-18T19:50:22.116339+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Artiva stockholders approve 1.2M share increase to 2024 equity plan, re-elect director Baker","bullets":["Amendment to 2024 Equity Incentive Plan approved, adding 1,214,580 shares to the share reserve; total now up to 7,001,185 shares.","Class I director Daniel Baker, Ph.D., re-elected with 18.9M votes for (98.9% of votes cast), 22,995 withheld.","KPMG LLP ratified as independent auditor for FY2025 with 20.8M votes for, 300 against, 2,272 abstain.","Plan also provides annual automatic increase of up to 5% of outstanding shares each January 1 through 2034."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-089942","json":"https://secwatch.observer/filing/0000950170-25-089942.json","markdown":"https://secwatch.observer/filing/0000950170-25-089942.md","text":"https://secwatch.observer/filing/0000950170-25-089942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025089942/0000950170-25-089942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025089942/artv-20250624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:50:22.116339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}